Literature DB >> 10466552

Results of a comprehensive infection control program for reducing surgical-site infections in coronary artery bypass surgery.

S J McConkey1, P B L'Ecuyer, D M Murphy, T L Leet, T M Sundt, V J Fraser.   

Abstract

OBJECTIVE: To evaluate the efficacy of a comprehensive infection control program on the reduction of surgical-site infections (SSIs) following coronary artery bypass graft (CABG) surgery.
DESIGN: Prospective cohort study.
SETTING: 1,000-bed tertiary-care hospital. PATIENTS: Persons undergoing CABG with or without concomitant valve surgery from April 1991 through December 1994.
INTERVENTIONS: Prospective surveillance, quarterly reporting of SSI rates, chlorhexidene showers, discontinuation of shaving, administration of antibiotic prophylaxis in the holding area, elimination of ice baths for cooling of cardioplegia solution, limitation of operating room traffic, minimization of flash sterilization, and elimination of postoperative tap-water wound bathing for 96 hours. Logistic regression models were fitted to assess infection rates over time, adjusting for severity of illness, surgeon, patient characteristics, and type of surgery.
RESULTS: 2,231 procedures were performed. A reduction in infection rates was noted at all sites. The rate of deep chest infections decreased from 2.6% in 1991 to 1.6% in 1994. Over the same period, the rate of leg infections decreased from 6.8% to 2.7%, and of all SSI from 12.4% to 8.9%. The adjusted odds ratio (OR) for all SSIs for the end of 1994 compared to December 31, 1991, was 0.37 (95% confidence interval [CI95], 0.22-0.63). For deep chest and mediastinal infections, the adjusted OR comparing the same period was 0.69 (CI95, 0.28-1.71).
CONCLUSIONS: We observed significant reductions in SSI rates of deep and superficial sites in CABG surgery following implementation of a comprehensive infection control program. These differences remained significant when adjusted for potential confounding covariables.

Entities:  

Mesh:

Year:  1999        PMID: 10466552     DOI: 10.1086/501665

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  7 in total

1.  Nonconcordance with surgical site infection prevention guidelines and rates of surgical site infections for general surgical, neurological, and orthopedic procedures.

Authors:  Barnaby Young; Tat Ming Ng; Christine Teng; Brenda Ang; Hwei Yee Tai; David C Lye
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 2.  Safety in the operating theatre--a transition to systems-based care.

Authors:  Thomas G Weiser; Michael P Porter; Ronald V Maier
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

3.  [Responsibility of surgeons for surgical site infections].

Authors:  P Gastmeier; C Brandt; D Sohr; H Rüden
Journal:  Chirurg       Date:  2006-06       Impact factor: 0.955

4.  Postoperative antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery: a retrospective cohort study.

Authors:  C-J Busch; R Knecht; A Münscher; J Matern; C Dalchow; B B Lörincz
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-18       Impact factor: 2.503

5.  Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial.

Authors:  Kay Dhadwal; Sharif Al-Ruzzeh; Thanos Athanasiou; Marina Choudhury; Paris Tekkis; Pynee Vuddamalay; Haifa Lyster; Mohamed Amrani; Shane George
Journal:  Heart       Date:  2007-02-19       Impact factor: 5.994

6.  [Quality assurance and infection control in outpatient surgery].

Authors:  A Blaich; R Babikir; F Daschner; M Schweins; J Lambert; E Ingenhoven; P Gastmeier; M Dettenkofer
Journal:  Chirurg       Date:  2007-07       Impact factor: 0.920

Review 7.  Prevention of hospital-acquired infections: review of non-pharmacological interventions.

Authors:  L T Curtis
Journal:  J Hosp Infect       Date:  2008-06-02       Impact factor: 3.926

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.